Cartesian Therapeutics, Inc. (RNAC)
After hours:
| Previous close | 16.58 |
| Open | 16.96 |
| Bid | 16.96 x 100 |
| Ask | 17.77 x 100 |
| Day's range | 16.22 - 17.76 |
| 52-week range | 11.66 - 42.60 |
| Volume | |
| Avg. volume | 151,320 |
| Market cap | 373.927M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -56.06 |
| Earnings date | 15 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.83 |
GlobeNewswireCartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On July 1, 2024, the Company issued to these employees options to purchase an aggregate of 35,198 shares of the Company’s common stock with an exercise price of $24.27, the closing trading price of the Comp
Investor's Business DailyCartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs
Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.
- GlobeNewswire
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertiseGAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise
